Clinical Trials

A Phase I Study of Narnatumab (IMC-RON8) in Patients with Refractory Solid Tumors

Protocol
13-018
Full Title
Phase 1 Study of the Anti-RON Receptor Monoclonal Antibody Narnatumab (IMC RON8) in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy is Available
Purpose

The purpose of this study is to find the highest dose of an investigational drug called narnatumab (IMC-RON8) that can be given in patients with advanced solid tumors that have continued to grow despite standard therapy or for which no standard therapy exists. Narnatumab works by targeting a protein called RON8 that is believed to stimulate cancer cell growth. This drug is given intravenously (by vein).

Investigator
Pictured: Mrinal M. Gounder, MD
Mrinal M. Gounder - Physician Profile
Co-Investigators
Pictured: Martin H. Voss
Martin H. Voss - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Have advanced cancer (solid tumor) that is not responding to standard therapy or for which no standard therapy exists.
  • Have completed prior therapies at least 4 weeks before starting therapy with narnutumab (6 weeks since any antibody therapies).
  • Recovered from any serious side effects of previous treatment before entering the study.
  • Be able to be ambulatory for more than half of normal waking hours.
  • Be age 18 and older.

Please discuss with your primary oncologist whether this clinical trial is appropriate for you.

For more information about this study and to inquire about eligibility, please contact Dr. Mrinal Gounder at 646-888-4167.

Disease(s)
Solid Tumors
Locations